Designer Baby Companies Are in Turmoil
Two companies, Manhattan Genomics and Bootstrap Bio, that aimed to create gene-edited babies have shut down due to financial issues and internal conflicts. The companies' ambitions to edit DNA in human embryos were met with controversy and concerns over safety and efficacy.
Two companies that planned to create gene-edited babies have shut down. Manhattan Genomics of New York closed abruptly after announcing a team of scientific advisers in October. California-based Bootstrap Bio ceased operations in late 2025, citing financial issues. The companies aimed to edit DNA in human embryos to prevent serious diseases, but the technology is highly controversial and unproven. Bootstrap Bio's CEO stated that they ran out of money and couldn't secure enough investors. The company's chief science officer was arrested in August 2025 on charges of attempted sex trafficking of a child. Gene editing in human embryos is currently prohibited in the US and many other countries.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.